Navigation Links
Medical Futures signs North American licensing rights to New Biologic agent for Ulcerative Colitis
Date:4/7/2008

TORONTO, April 7 /PRNewswire/ - Medical Futures Inc. has licensed MUTAFLOR(R) for the North American market. MUTAFLOR(R) is a drug used in remission maintenance of Ulcerative Colitis. Since its discovery in 1917, MUTAFLOR(R) has been available in the German marketplace through a subsidiary of Pharma-Zentrale GmbH, Ardeypharm GmbH. MUTAFLOR(R) has shown clinical efficacy in phase III clinical trials and has shown a perfect safety record since 1917. Ulcerative colitis is an Inflammatory Bowel Disease that affects 500,000 Americans and 60,000 Canadians.

"Medical Futures Inc. is excited about partnering with Pharma-Zentrale GmbH for MUTAFLOR(R)," says Dr. Par Nijhawan, Chief Medical Officer of Medical Futures Inc., who believes that MUTAFLOR(R) will help improve the options available for Ulcerative Colitis patients.

"Medical Futures has created a therapeutic focus and a strong product offering for the gastroenterology market in North America," says Hans Proppert, President and Chief Executive Officer of Pharma Zentrale GmbH. "With MUTAFLOR(R) in their capable hands, we are confident of its success in an important market for us."

About MUTAFLOR(R)

MUTAFLOR(R) has data proving equal efficacy when compared to 5-ASA products in remission maintenance of Ulcerative Colitis. It is taken as an oral capsule format that saves patients from intravenous infusions or self administration of subcutaneous needles. This, together with the clinical evidence, is one advantage of MUTAFLOR(R) over all other biologics available on the market.

About Medical Futures Inc.

Medical Futures Inc. is a niche pharmaceutical company that has a focus on gastrointestinal therapy. Medical Futures is dedicated to improving quality of life and provides safe, effective and affordable medicines. These medicines include:

Florastor(TM): The world's number one probiotic that has proven efficacy in treating and preventing diarrhea from various causes including Pediatric Diarrhea, Antibiotic Associated, Clostridium Difficile and Travellers' Diarrhea.

Iberogast(R): The only treatment available for Non-ulcer Dyspepsia and Irritable Bowel Syndrome.

Zingo(TM) is a needle-free, easy-to-administer, single-use system that delivers sterile lidocaine powder into the epidermis of the skin that provides topical, local analgesia in one minute.

SANVAR(R) is the only somatostatin analogue to have demonstrated statistically significant benefits in the treatment of esophageal variceal bleeding in association with endoscopic therapy in a placebo-controlled clinical study (NEJM, 2001).


'/>"/>
SOURCE Medical Futures Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MSU engineering team designs innovative medical device
2. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
4. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
5. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
6. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
7. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
8. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
9. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
10. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
11. FDA Seeks to Regulate Complementary and Alternative Medicine; Products Such as Vegetable Juice Could Be Restricted for Medical Use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... ... Image One USA veteran franchise owner Maria Bogacki is bringing ... Nashville that will benefit. , “I’ve enjoyed being a part of the Image One ... question that I would bring my business with me,” Bogacki said. “The entire Image ...
(Date:2/11/2016)... ... February 11, 2016 , ... The ... among the top five firms in the “2015/2016 Best in KLAS: Software and ... Staffing. KLAS is a research and insights firm on a global mission to ...
(Date:2/11/2016)... FL (PRWEB) , ... February 11, 2016 , ... ... and advocates will discuss how to improve care by making data on heart ... heart disease. The Summit on Transparency and Public Reporting of Pediatric and Congenital ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... Surgery, Dallas plastic surgeon , Dr. Rod J. Rohrich, and colleagues, examine ... Dr. Rohrich outlines recommendations for rhinoplasty surgeons when addressing this vital area. , ...
(Date:2/11/2016)... ... February 11, 2016 , ... veEDIS Clinical ... technology, with highly adaptable algorithms, has been updated to help Emergency Department physicians ... symptoms consistent with Zikas and a travel history to affected regions, or potential ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... 2016 Potrero Medical, Inc., the developer of the ... appointment of George M. Rapier, III , MD, to ... , WellMed is one of the nation,s largest physician ... members in Texas and ... his own internal medicine practice, he has been instrumental to ...
(Date:2/11/2016)... AAIPharma Services Corp./Cambridge Major Laboratories, Inc. ... development services for the pharmaceutical and biotechnology industries, ... in its Charleston, SC ... recent investments. Charleston ... with small-scale lyophilization. The site has invested in ...
(Date:2/11/2016)... SEOUL, South Korea , Feb. 11, 2016 Wearable posture tracker, ALEX , has ... project fully funded and just seven days left to go, ALEX is said to be delivered to ... http://photos.prnewswire.com/prnh/20160211/332248 ... ... ...
Breaking Medicine Technology: